Euthymics Bioscience Secures $4,000,000 Series A Round

  • Feed Type
  • Date
    3/9/2011
  • Company Name
    Euthymics Bioscience
  • Mailing Address
    43 Thorndike St. Cambridge, MA 02141
  • Company Description
    Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment.
  • Website
    http://www.Euthymics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $4,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    This is an add on to the existing series A. According to Euthymics officials, the new funds will be used to move forward preclinical development of its second product candidate EB-1020, a non-stimulant for adult ADHD (attention deficit/hyperactivity disorder).
  • M&A Terms
  • Venture Investor
    Undisclosed